Navigation Links
U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta
Date:4/27/2011

INDIANAPOLIS, April 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.  

The order came in the case of Eli Lilly and Company v. Wockhardt Limited, et al. The Court had initially entered final judgment against Wockhardt on March 21, 2011.  As part of today's Court order, the defendants are further required to notify the Food and Drug Administration that they are no longer seeking approval for a generic duloxetine product during the patent term. In light of the parties' stipulation to the Court's order, the litigation has been dismissed and no appeal is possible.  

"We are very pleased with the District Court's order that effectively maintains U.S. exclusivity for Cymbalta throughout its patented life," said Robert A. Armitage, senior vice president and general counsel for Lilly. "Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Cymbalta patent litigation. These statements are based on management's current expectations but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Cymbalta® (duloxetine hydrochloride, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
2. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
3. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
4. Sensipar® Patents Upheld By District Court
5. Winner Medical Honored with Shenzhen Baoan District Quality Award
6. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
7. German District Court Finds RENASYS™ GO NPWT System Non-infringing
8. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
9. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
10. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
11. McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):